chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Injection pain site; tiredness; slight headache; nausea; general malaise; This is a spontaneous report received from a contactable health care professional, the patient. A 58-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8732) via an unspecified route administration in the right arm on 27Mar2021 at 10:15 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. The patient was allergic to codeine. The concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 06Mar2021 at 09:15 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior of the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. On 27Mar2021 at 14:00 the patient experienced injection site pain (vaccination site pain), tiredness, slight headache, nausea and general malaise. The patient underwent lab investigations for COVID-19 with nasal swab test on 11Feb2021 and was tested negative. The patient did not receive any treatment for the events. The clinical outcome of the events vaccination site pain, tiredness, slight headache, nausea and general malaise were not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Severe diarrhea (more than 10 episodes per day), racing heart, dizziness, migraine
Rash on right arm; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ep6955), via an unspecified route of administration in left arm on 21Mar2021 at 12:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and penicillin allergy. concomitant medication was not reported. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 17:00, the patient experienced a rash on the right arm. The patient did not receive treatment for the reported event. The event did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care The clinical outcome of the event rash on right arm was resolved with lasting effects on an unspecified date in Mar2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Firm hive-like welt under skin approximately half-dollar in size with itching and redness persistent for 72 hours and has not resolved as of report
Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies; Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies; Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies; This literature marketed report has been received from authors of a published article, referring to an unknown age patient with ataxia telangiectasia (primary immunodeficiency diseases (PID)). Information about concomitant medication and medical history was not provided.  On an unknown date, at about one year old, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(manufacturer unknown) (dose, route, lot# and expiration date were unknown) for prophylaxis. On an unknown date, the patient developed cutaneous granulomatous lesions in different body sites, e.g. face, chest, arms or legs, at various times after vaccination. No pathogenic organisms were identified by the histochemical staining or bacterial, fungal and mycobacterial cultures. Rubella viruses (RV) antigen was detected in the available tissue sections of cutaneous granulomas by fluorescent immunohistochemical staining for measles and rubella antigens. Live vaccines, including rubella vaccine, were contraindicated for individuals with severe antibody deficiency, T-cell deficiencies or innate immune defects because they may cause severe or chronic disease.   The outcome of the events was unknown. The reporter considered the events to be related to measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(manufacturer unknown).    A copy of the published article is attached as further documentation of the patient's experience.  This is one of several reports received from the same literature.; Sender's Comments:  US-009507513-1911USA008596:
Swelling and pain in right arm with rotator cuff issues. Pt had rotator cuff repair surgery in Feb. 2017.
He had soreness, fatigue and radiating arm pain for days. Our entire family of 5 experienced a strange metallic taste in our mouths after his 2nd dose. That lasted about 2 weeks. We also started experiencing bizarre sensations inside our craniums-it felt like something warm was spreading in our brains. I immediately administered high doses of glutathione to myself and the children, which stopped all of our symptoms. It was apparent to me that the "vaccine" was spreading from the injected to the rest of us and causing us all to become sick. I read about it happening on the Moderna website after the fact, so I know it wasn't imaginary.  Additionally, just last week patient was admitted to a private medical facility where he was experiencing severely elevated heart rate and severely elevated blood pressure.
Fever blister; This spontaneous case was reported by a consumer and describes the occurrence of ORAL HERPES (Fever blister) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ORAL HERPES (Fever blister). At the time of the report, ORAL HERPES (Fever blister) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       The patient had acyclovir she usually took for the blisters but had not taken any yet.  The patient had gotten fever blisters since the patient was a child and this was not out of the ordinary. No concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 27-Apr-2021: Updated second dose had taken and event history. On 12-Jul-2021: Follow up received and contains No New Information.
Patient had injection site reaction that appeared the day after vaccination. Symptoms inlude itch, swelling, redness, and hardening of the skin.  Size of the area increased to a diameter of about 2.5 to 3 inches.  Symptoms persisted for almost a week. Patient self-treated with hydrocortisone cream and cold-compress.
he had fever; strong pain under armpit and injection site.; very painful lump under the armpit/strong pain under armpit; very painful lump under the armpit; This is a spontaneous report from a contactable consumer (patient) reported for himself.  A 50-year-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: ER8733, Expiry date: unknown), via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunisation. The medical history was not reported. There were no concomitant medications. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported, Expiry date: unknown), via an unspecified route of administration, administered on an unspecified date as dose 1, single for covid-19 immunisation. As per the report, he was vaccinated on Friday and on an unspecified date on Saturday, he had fever and a strong pain under armpit and injection site. Consumer reported that he has a very painful lump under the armpit. The outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This case was reported by a consumer via call center representative and described the occurrence of injection site discomfort in a male patient who received SHINGRIX for prophylaxis. On 17th July 2018, the patient received the 2nd dose of SHINGRIX. In July 2018, less than a week after receiving SHINGRIX,  the patient experienced injection site discomfort. On an unknown date, the outcome of the injection site discomfort was unknown. It was unknown if the reporter considered the injection site discomfort to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient had some discomfort at the injection site.
Increase in arthritis/joint pains starting day after vaccine; Intermittent headaches.  12 days after vaccine, patient donated blood.  13 days after vaccine with chills, fatigue, body aches, headache, feeling feverish, but normal temperature, right neck gland swollen
low grade fever; tired; sleeping a lot; chills; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (sleeping a lot), CHILLS (chills), PYREXIA (low grade fever) and FATIGUE (tired) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013A21A) for COVID-19 vaccination.     Concurrent medical conditions included Knee pain, Asthma, Chronic kidney disease stage 3 (Improved), Blood pressure high (Fairly stable), Depression (Increased Prozac dose), Allergic rhinitis, Drug allergy (Allergic to tylenol) and Environmental allergy (Allergic to (anything scented or fumes)). Concomitant products included NAPROXEN SODIUM (ALEVE) and PARACETAMOL (TYLENOL) for Knee pain.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced SOMNOLENCE (sleeping a lot) and CHILLS (chills). On 12-Mar-2021, the patient experienced PYREXIA (low grade fever) and FATIGUE (tired). At the time of the report, SOMNOLENCE (sleeping a lot) outcome was unknown and CHILLS (chills), PYREXIA (low grade fever) and FATIGUE (tired) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Mar-2021, Body temperature: 99.9 (High) 99.9 F low grade fever..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment informations were provided by the reporter.   This case was linked to MOD-2021-114453 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up received on 14-Jul-2021. Event outcomes were updated. Current conditions and allergy were included.
vague neurological symptoms; This is a spontaneous report received from contactable reporter(s) (Physician).  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization.  The following information was reported: NEUROLOGICAL SYMPTOM (non-serious), outcome "unknown", described as "vague neurological symptoms".  Additional information: Physician reported two cases of potential adverse events related to COVID vaccination. He had no specific details of either patient, though he was going to look into each for us. One case was a person who developed vague neurological symptoms weeks after the vaccination; and one who has a diagnosis of an underlying autoimmune disease who might have had an exacerbation post vaccination and post illness [actually had COVID as well] at an indistinct time period.   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
received a full dose of moderna as my booster; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL OVERDOSE (received a full dose of moderna as my booster) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACCIDENTAL OVERDOSE (received a full dose of moderna as my booster). At the time of the report, ACCIDENTAL OVERDOSE (received a full dose of moderna as my booster) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported.  The patient received a full dose of Moderna as their booster dose because their previous pharmacy did not register their 2nd dose to agency, but all info.  No treatment information was provided.
Information has been received from a licensed practical nurse concerning a 65 year old patient of unknown gender. The patient did not have pertinent medical history. The patient had no know allergies. On 13-OCT-2015, the patient was vaccinated with a dose of PNEUMOVAX23, lot # K008927 (dose not reported), expiration date 17-MAR-2016, intramuscularly. The patient did not take concomitant therapy. On an unknown date in October 2015, the patient experienced unspecified rash at injection site, red, tender and diagnosed as cellulitis. The patient contacted the office to seek medical attention on 15-OCT-2015 (today), and was seen by a clinician in the office. The patient started on doxycycline for the event. No lab diagnostics studies were performed. The outcome of the event was unknown. This is one of three reports received from the same source. Additional information has been requested.
Rapid swelling, erythema, urticaria,  Increased over the next 36 hours, treated with Benadryl, Zyrtec, and famotidine.  Significant bruising resolved for next 7 days
Fever, chills, nausea, vomiting on seventh day, exhaustion, Headache, diarrhea, body aches and pains. All are still being g felt since my second shot. Stopped vomiting but experiencing all of the rest of the symptoms to date intermittently but regularly.
pt recv vax 28JUL95 & 1FEB95 pt devel 4 to 5 chicken pox lesions over trunk & exp a red throat;
Issues with blood sugar levels. Had issue 2 weeks after 2nd dose and am having same issue 2 weeks after booster dose. Eating same meal for lunch every day that I've been eating for months and have issues with my sugar dropping below 70. Lasted for a week after 2nd dose and is now on day 2 of low sugar during midday / afternoon after booster shot.
Heart palpatations one day after being administered 5th dose of rabies vaccine.  Previous series of rabies vaccines did not reach titer so I needed to get a 5th shot.
1st dose Sep 3rd 2020, 2nd not yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 85-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 3rd September 2020).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.    Additional Information: GSK Receipt Date: 09-SEP-2022 Reporter's Comments: The pharmacist had a patient that never received Shingrix second dose and received First dose only. The reporter consent to follow up. Additional Supportive Information: Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
She has soreness in arm; Stomach ache; Pain in shoulder near collar bone; Pain in arm of injection; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (She has soreness in arm), ABDOMINAL PAIN UPPER (Stomach ache), ARTHRALGIA (Pain in shoulder near collar bone) and VACCINATION SITE PAIN (Pain in arm of injection) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced VACCINATION SITE PAIN (Pain in arm of injection). On 17-Feb-2021, the patient experienced PAIN IN EXTREMITY (She has soreness in arm), ABDOMINAL PAIN UPPER (Stomach ache) and ARTHRALGIA (Pain in shoulder near collar bone). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at a dose of 1 dosage form. On 11-Feb-2021, VACCINATION SITE PAIN (Pain in arm of injection) had resolved. At the time of the report, PAIN IN EXTREMITY (She has soreness in arm), ABDOMINAL PAIN UPPER (Stomach ache) and ARTHRALGIA (Pain in shoulder near collar bone) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant medication not reported.   This case was linked to MOD-2021-175651 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: updated outcome of the events to recovered.
Headache; experienced a side effect.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) and ADVERSE REACTION (experienced a side effect.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Headache) and ADVERSE REACTION (experienced a side effect.). At the time of the report, HEADACHE (Headache) and ADVERSE REACTION (experienced a side effect.) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 25-May-2021: Follow-up information received on 26-MAY-2021 contains non-significant information.
Fever. T 101 F; The flu like symptoms lasted about 36 hours; headache; chills; Tiredness; Went to sleep early; This is a spontaneous report from a contactable Nurse.  A 48-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular on 05Jan2021 14:00 for the 2nd dose at single dose, intramuscular on 18Dec2020 11:00 for the 1st dose at single dose for covid-19 immunisation.  Medical history included I am allergic to pollen, dust mite.  The patient experienced Four hours after 2nd shot, headache, chills. Tiredness. Went to sleep early. The next day still tiredness, headache , chills and fever. T 101 F. The flu like symptoms lasted about 36 hours. All events were non serious. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No treatment received for the adverse event. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was resolved.  No follow up attempts are possible; information about lot/batch number cannot be obtained.
Information regarding Prevnar was received from a healthcare professional regarding a 2 year old male patient who developed pneumococcal disease. The patient received the fourth dose on an unspecified date. Relevant medical history was not provided. Indication for Prevnar was immunization. Product was administered on an unspecified date. Dose regimen was 1 dose. Concomitant medications were not reported. On an unspecified date the patient developed pneumococcal disease and subsequently died. The cause of death was reported as pneumococcal infection. No additional information was available at the time of this report. Medical records from Vanderbilt U. Clinic received which revealed patient had hx of sickle cell anemia w/recent fever. Autopsy report received which revealed COD as sepsis due to streptococcus pneumonia.  Also found hepatosplenomegaly, interstitial pneumonitis with nasal swab recently + for flu virus, diffuse abdominal lymphadenopathy secondary to follicular hypoplasia and cerebral edema.
So tired, feel like I can?t breathe, sleeping too much, brain fog unlike I?ve ever experienced, arthritis and body aches I?ve never experienced like this before, chest pains, out of breath doing daily chores. I?ve always considered myself healthy.   I did not go to the doctor because I kept thinking this would be temporary. I?m filling this out because it?s important to know these vaccines have serious side effects. Months later I?m still not myself. I?ve never tested positive for Covid.
Moderna Covid19 Vaccine EUA. The day after i received the vaccine i got a red swollen circle on the injection site area. The circle was about 2 inches in diameter and very swollen. It felt warm to the touch. It was a little itchy at times. It felt a little sore if I touched the area. Everyday after that the swelling went down and became less red. On the 8th day I thought it would be gone but the swelling came back. It is about 2 inches in diameter, red in color, warm to the touch and a little itchy. It's not as swollen as before but still feels sore to the touch.
Extreme fatigue; Severe headache; Neck / arm pain; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 11Jun2021 at 14:00(at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Concomitant medications included blood pressure (MANUFACTURER UNKNOWN) and PREMARIN taken for unknown indication from an unknown start date. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20May2021 at 13:00(at the age of 53-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Jun2021, the patient experienced extreme fatigue lasting 3+ days, severe headache and neck / arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of these events.  The clinical outcome of the events extreme fatigue, severe headache and neck / arm pain was recovering at the time of this report.   The batch/lot numbers for BNT162b2 were not provided and will be requested during follow up.